Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Medanta expanded its bed capacity by 20% during the year
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
NEJM study shows strong protection across strains
Subscribe To Our Newsletter & Stay Updated
